PIK3CA and breast cancer: In patients with PI3K pathway–altered breast cancer (n = 234), the median TTNT was 5.2 months (95% CI, 4.2–6.0) and the median TTD was 4.0 months (95% CI, 3.4–4.2; Fig. 5A and B).